HELP NASDAQ
Cybin Inc. Common Stock
1W: -16.2%
1M: -12.0%
3M: -37.1%
YTD: -47.6%
$4.34
+0.16 (+3.83%)
Weekly Expected Move ±13.8%
$3
$4
$5
$5
$6
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$216.5M
52W Range4.15-9.83
Volume522,535
Avg Volume1,201,781
Beta0.81
Dividend—
Analyst Ratings
Company Info
CEOMichael F. Cola
Employees50
SectorHealthcare
IndustryBiotechnology
IPO Date2019-09-13
Websitecybin.com
100 King Street West
Toronto, ON M5X 1C9
CA
Toronto, ON M5X 1C9
CA
908 764 8385
About Cybin Inc. Common Stock
Clinical-stage biopharmaceutical company developing psychedelic-based therapeutics including CYB003 (deuterated psilocybin analog) for major depressive disorder and CYB004 (deuterated DMT) for generalized anxiety disorder
Latest News
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
Helus Pharma CEO Michael Cola steps down; Eric So takes interim CEO role
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions
Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research
Recent Insider Trades
No insider trades found